What Percentage of Diabetics Go Blind?

Roughly one in a hundred people with diabetes develops significant visual impairment from diabetic retinopathy, and the percentage who go completely blind is smaller still. A 2024 meta-analysis estimated that about 1.07 million people worldwide were blind due to diabetic retinopathy in 2020, with the condition accounting for around 2.5% of all global blindness.¹ In the developed world, the share is higher, with diabetic retinopathy responsible for over 15% of blindness cases.² Those numbers, while serious, are far lower than many people fear at the time of a diabetes diagnosis, and they have been dropping for decades thanks to better screening and treatment.

Where the “Diabetes Causes Blindness” Fear Comes From

Diabetic retinopathy is the most common complication of diabetes overall, showing up in at least one out of every three people with the disease.² That statistic alone is alarming enough to make “going blind” feel inevitable. But having retinopathy and going blind are very different things. Most retinopathy is mild and non-proliferative, meaning the blood vessels in the retina show early damage like tiny swellings or small hemorrhages, but vision stays intact. Only when the disease progresses to its advanced, proliferative stage does the eye start growing fragile new blood vessels that can bleed, scar, and pull the retina away from its normal position. Proliferative diabetic retinopathy is the leading cause of blindness among working-age adults in many countries, but it represents the far end of a long spectrum that most people with diabetes never reach.

The confusion partly comes from how statistics are reported. “Any retinopathy” captures everything from a few harmless microaneurysms to severe, sight-threatening disease. When someone reads that a third of all diabetics have retinopathy, they picture the worst outcome. In reality, the vast majority of that third has early-stage changes that can be managed or even reversed with good metabolic control.

Type 1 Versus Type 2 Diabetes

The risk profile differs substantially depending on which type of diabetes you have. A nine-year follow-up study found that the cumulative incidence of any retinopathy was about 47% in people with type 1 diabetes and about 26% in those with type 2.³ Sight-threatening forms of retinopathy were also roughly twice as common in the type 1 group over that period. The main reason is duration: type 1 diabetes usually starts in childhood or adolescence, so by middle age many of these patients have lived with the disease for decades. Type 2 diabetes tends to develop later in life, giving the eyes less total exposure to high blood sugar.

That said, type 2 diabetes accounts for about 90% of all diabetes cases worldwide, so in absolute numbers, far more people with type 2 end up with retinopathy simply because the population is so much larger. And because type 2 can simmer undiagnosed for years, some people already have retinal changes by the time they learn they have diabetes at all.

What Drives the Risk

Three factors matter more than almost anything else: how long you have had diabetes, how well your blood sugar has been controlled, and your blood pressure.

Duration is the single strongest predictor. One study found that people who had lived with diabetes for five years or more had nearly three times the hazard of developing retinopathy compared with those diagnosed more recently.⁴ The 25-year Wisconsin study of type 1 diabetes tracked visual impairment over a quarter century and found that the risk of any visual impairment kept climbing with both age and duration; factors that independently raised the risk included more severe retinopathy at baseline, higher HbA1c, the presence of cataracts, hypertension, and smoking.⁵

Blood sugar control, measured by HbA1c, has a complicated relationship with eye disease. A large Swedish population study found that maintaining HbA1c in the range of 6.5–6.9% was associated with a lower risk of severe retinopathy compared with levels both above and below that window.⁶ Pushing HbA1c below 6.5% did not appear to offer additional eye protection and came with a higher risk of severe hypoglycemia. The practical takeaway is that steady, moderate control matters more than chasing the lowest possible number.

Blood pressure and cholesterol round out the picture. A clinical study of type 2 diabetes patients found strong associations between elevated HbA1c (above 9%), high blood pressure (above 160/90), and high cholesterol (above 200 mg/dL) with the development of ocular complications including cataracts, retinal detachment, and internal hemorrhage.⁷ Elevated diastolic blood pressure in particular remained a significant predictor of cataract development even after adjusting for diabetes duration and HbA1c.⁸

Diabetic Macular Edema as a Separate Threat

Not all diabetes-related vision loss comes from proliferative retinopathy. Diabetic macular edema, or DME, is actually the most common cause of visual impairment in people with diabetes.⁹ DME happens when fluid leaks into the macula, the small central area of the retina responsible for sharp, detailed vision. You can have DME at any stage of retinopathy, including mild stages, which is part of why regular screening matters even when retinopathy looks early on paper.

The location and duration of the swelling largely determine how much vision is lost. A study of eyes with DME found that when the swelling involved the very center of the fovea, sustained moderate vision loss was far more common, occurring in about 73% of eyes that experienced lasting visual decline. Visual acuity dropped progressively with both increasing retinal thickness at the center and longer duration of center-involving edema.¹⁰ The good news is that DME is now highly treatable with injections that target the abnormal blood vessel growth driving the leakage.

Eye Problems Beyond Retinopathy

Retinopathy and macular edema get most of the attention, but diabetes raises the risk of several other eye conditions that can contribute to vision loss. Cataracts develop earlier and more frequently in people with diabetes, accelerated by the same metabolic factors that damage the retina. Glaucoma, particularly a form called neovascular glaucoma, is another concern. In one study, diabetic patients who underwent cataract surgery had a statistically significant rate of postoperative neovascular glaucoma (about 8%) compared with zero in non-diabetic controls. In patients who already had active proliferative retinopathy before surgery, that rate jumped to 40%.¹¹ These numbers underscore why even routine eye procedures require careful planning when diabetes is in the picture.

Screening Catches Problems Before They Steal Vision

The single most effective intervention against diabetes-related blindness is regular eye screening. Vision loss from diabetic retinopathy is largely preventable if the disease is caught at early stages and referred for timely treatment.¹² A striking example comes from Stockholm, where systematic screening programs helped reduce new cases of diabetes-related blindness by more than a third over a fifteen-year period, with a mean yearly reduction of about 11%.¹³

Yet screening rates remain stubbornly low in many populations. In the United States, lower income, lower education, and lack of insurance coverage are all associated with reduced access to diabetic eye screening.¹⁴ Where you live matters as well. Black patients with diabetes living in rural communities had 88% lower odds of receiving eye-care visits compared with Black patients in urban areas, and White patients in rural areas had 25% lower odds compared with their urban counterparts.¹⁵ Insurance type played a role too, with patients on Medicare or Medicaid having lower odds of eye-care visits than those with commercial insurance. Globally, unawareness of the need for screening is itself a barrier, particularly in populations with lower education and literacy levels.¹⁶

How Treatments Have Changed the Odds

Decades ago, laser photocoagulation was the main weapon against proliferative diabetic retinopathy, and it made a real difference. The landmark Early Treatment Diabetic Retinopathy Study showed that early photocoagulation reduced the risk of severe visual loss, with a particularly strong benefit in patients with type 2 diabetes.¹⁷ Laser treatment works by destroying small areas of the peripheral retina to reduce the oxygen demand that drives abnormal new vessel growth. It saves central vision at the cost of some peripheral and night vision.

The treatment landscape has shifted dramatically in recent years. Between 2016 and 2023 in the United States, laser treatment rates for proliferative diabetic retinopathy dropped by about a quarter, while anti-VEGF injection rates rose by roughly 60%.¹⁸ Anti-VEGF drugs block the signal that tells the eye to grow leaky new blood vessels, and they can stabilize or even improve vision without the permanent retinal destruction that laser requires. The catch is that they need to be injected into the eye repeatedly, sometimes monthly for extended periods, which creates its own burden in terms of cost, travel, and compliance.

Artificial Intelligence in Screening

One of the most promising developments in preventing diabetes-related blindness is the use of AI systems to screen retinal photographs. These tools can be deployed in primary care clinics, pharmacies, or community health centers, removing the bottleneck of needing an eye specialist for the initial screen. In a direct comparison, one AI system detected more-than-mild diabetic retinopathy with a sensitivity of about 96%, compared with roughly 28% for dilated examination by ophthalmologists. Retina specialists did better than general ophthalmologists, but even they caught fewer cases than the automated system.¹⁹

An AI model tested in India showed similarly strong performance, with sensitivity above 93% and specificity above 95% for detecting referable retinopathy.²⁰ A policy model estimated that if AI screening were combined with maximized treatment adherence, the number of people with any vision loss at five years could drop to roughly 1,167 per 100,000, compared with about 1,488 per 100,000 under a traditional eye-care-provider strategy.²¹ The advantage comes from AI’s ability to screen more people faster and flag problems earlier, particularly in underserved areas where ophthalmologists are scarce.²²

Pregnancy and Diabetic Eye Disease

Women who have diabetes before becoming pregnant face a temporary but real spike in retinopathy risk. Progression of existing retinopathy changes occurs in roughly 50–70% of pregnancies, with the greatest risk during the second trimester. The changes can persist for up to 12 months after delivery.²³ The physiological shifts of pregnancy, including metabolic, vascular, and hormonal changes, can both trigger new retinopathy and worsen what is already there.²⁴ This is why guidelines recommend that women with pre-existing diabetes have a thorough eye exam before or early in pregnancy, with follow-up throughout. Reassuringly, pregnancy does not appear to cause long-term worsening; the retinopathy that flares during pregnancy often stabilizes or even regresses afterward.

When Vision Loss Complicates Diabetes Management Itself

There is a vicious cycle that rarely gets discussed: once diabetes damages your eyesight, managing the diabetes itself becomes harder. Qualitative research with diabetic patients who had developed retinopathy revealed that many struggled with basic self-care tasks. Patients described being unable to read their blood sugar monitors accurately, sometimes misreading the display and confusing numbers like 411 for 114, leading to dangerous insulin dosing errors.²⁵ Counting insulin units, reading food labels, and navigating medical appointments all become more difficult. This cycle of impaired vision leading to worse blood sugar control, which in turn accelerates further eye damage, makes early intervention all the more critical.

Bariatric Surgery and Retinopathy

Weight-loss surgery has become an increasingly common intervention for type 2 diabetes, and its effects on eye disease are mixed. A comprehensive review found that the majority of diabetic retinopathy cases remain stable after bariatric surgery, and some even improve. However, the risk of progression or new retinopathy is not eliminated. Instances of worsening were linked to the severity of retinopathy already present at the time of surgery and, paradoxically, to the magnitude of the drop in HbA1c after the procedure.²⁶ Rapid improvements in blood sugar can temporarily worsen retinopathy, a phenomenon also seen when people start intensive insulin therapy for the first time. The long-term picture looks more favorable, with bariatric surgery potentially stabilizing progression and reducing the need for ongoing eye treatments.²⁷ If you are considering bariatric surgery and already have retinopathy, getting a thorough eye exam beforehand and close monitoring afterward is important.

Experimental Approaches on the Horizon

Current treatments focus on slowing or stopping damage that has already occurred. The next generation of therapies aims to prevent retinal damage at earlier stages or even reverse it. One line of research is exploring a protein called norrin, which targets the signaling pathway that maintains the blood-retina barrier. In diabetic rats, norrin treatment preserved visual acuity and contrast sensitivity, reduced retinal cell death and inflammation, and restored healthy gene expression patterns in the retina.²⁸ This is still animal research, and it could be years before human trials yield results, but it represents a fundamentally different approach: instead of burning away sick tissue with a laser or blocking vessel growth with drugs, the goal is to keep retinal cells healthy in the first place. Other approaches being explored include regenerative strategies and treatments tailored to individual patient variations in how the disease progresses.²⁹ The era of one-size-fits-all eye care for diabetes is gradually giving way to something more precise.